---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-035203"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:23:10.928600+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences raises $225M in oversubscribed PIPE at $7.50/share, 37% premium

## Summary
- Gross proceeds of $225M from 17.7M common shares at $7.50 and Series B convertible preferred.
- Pro-forma cash expected to fund into 2027 through SUMMIT, PEAK, and APEX registration trials.
- Led by Commodore Capital; includes Fairmount, Redmile, Janus, TCGX, Adage, Venrock, Deerfield, Perceptive.
- Investor webcast on Feb 23 to review SUMMIT Part 1b data at AAAAI annual meeting.

## SEC filing metadata
- accession: 0001193125-24-035203
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312524035203/0001193125-24-035203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312524035203/d790187d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-035203
- JSON: https://secwatch.observer/filing/0001193125-24-035203.json
- Plain text: https://secwatch.observer/filing/0001193125-24-035203.txt

## Key facts
- Governance Changes
  Cogent Biosciences, Inc.: Filed Certificate of Designation for Series B Non-Voting Convertible Preferred Stock, establishing the powers, preferences, rights, and limitations of the new series (effective 2024-02-14).
  - Change: charter amendment
  - Effective: 2024-02-14
  source text: On February 14, 2024, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock with the Secretary of State of the State of Delaware (the “ Certificate of Designation ”) in connection with the Private Placement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1622229/000119312524035203/0001193125-24-035203-index.htm
- Material Agreements
  Cogent Biosciences, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $225 million (effective 2024-02-13).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional and accredited investors
  - Value: approximately $225 million
  - Effective: 2024-02-13
  source text: On February 13, 2024, Cogent Biosciences, Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) for a private placement (the “ Private Placement ”) with certain institutional and accredited investors (each, a “ Purchaser ” and collectively, the “ Purchasers ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1622229/000119312524035203/0001193125-24-035203-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.